{"entity":{"id":"nct06560632","kind":"trial","name":"Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of RP-3467 run by Repare Therapeutics, terminated.","summary":"Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors is a phase 1 interventional study registered as NCT06560632 by Repare Therapeutics, with 26 participants enrolled, started 2024-09-17. Conditions recorded: Advanced Solid Tumor. Interventions recorded: RP-3467 at assigned dose and schedule and Olaparib 200-300 mg BID, daily.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06560632","url":"https://clinicaltrials.gov/study/NCT06560632"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["rp-3467"],"companies":["repare-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06560632","phase":"1","setting":"Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors (POLAR Trial)","sponsor":"Repare Therapeutics","enrolled":26,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06560632/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"rp-3467","kind":"drug","name":"RP-3467","route":"/drugs/rp-3467/"}],"company":[{"id":"repare-therapeutics","kind":"company","name":"Repare Therapeutics","route":"/companies/repare-therapeutics/"}]}}